$30,000 of EXELIXIS INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues."
You can find more data on corporate lobbying on Quiver Quantitative.
EXEL Insider Trading Activity
EXEL insiders have traded $EXEL stock on the open market 9 times in the past 6 months. Of those trades, 1 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $EXEL stock by insiders over the last 6 months:
- STELIOS PAPADOPOULOS sold 100,000 shares for an estimated $4,355,000
- PATRICK J. HALEY (EVP, Commercial) has made 0 purchases and 4 sales selling 72,230 shares for an estimated $3,046,928.
- DANA AFTAB (EVP, Research and Development) sold 48,383 shares for an estimated $2,056,277
- DAVID EDWARD JOHNSON purchased 27,532 shares for an estimated $1,187,234
- MARY C BECKERLE has made 0 purchases and 2 sales selling 24,622 shares for an estimated $1,032,413.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EXEL Hedge Fund Activity
We have seen 304 institutional investors add shares of EXEL stock to their portfolio, and 319 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FARALLON CAPITAL MANAGEMENT LLC added 3,466,000 shares (+21.6%) to their portfolio in Q3 2025, for an estimated $143,145,800
- ASSETMARK, INC added 2,955,813 shares (+1230.8%) to their portfolio in Q3 2025, for an estimated $122,075,076
- AQR CAPITAL MANAGEMENT LLC added 1,575,280 shares (+20.7%) to their portfolio in Q3 2025, for an estimated $65,059,063
- ALLIANZ ASSET MANAGEMENT GMBH added 1,490,520 shares (+153.3%) to their portfolio in Q3 2025, for an estimated $61,558,475
- VANGUARD GROUP INC removed 1,404,523 shares (-5.1%) from their portfolio in Q3 2025, for an estimated $58,006,799
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,394,104 shares (-45.7%) from their portfolio in Q3 2025, for an estimated $57,576,495
- UBS GROUP AG added 1,328,087 shares (+100.1%) to their portfolio in Q3 2025, for an estimated $54,849,993
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EXEL Analyst Ratings
Wall Street analysts have issued reports on $EXEL in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/08/2026
- TD Cowen issued a "Buy" rating on 11/05/2025
- Leerink Partners issued a "Outperform" rating on 10/21/2025
- Goldman Sachs issued a "Buy" rating on 09/17/2025
- Truist Securities issued a "Buy" rating on 07/29/2025
- JMP Securities issued a "Market Outperform" rating on 07/29/2025
To track analyst ratings and price targets for EXEL, check out Quiver Quantitative's $EXEL forecast page.
EXEL Price Targets
Multiple analysts have issued price targets for $EXEL recently. We have seen 14 analysts offer price targets for $EXEL in the last 6 months, with a median target of $47.5.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $52.0 on 01/08/2026
- Sean Laaman from Morgan Stanley set a target price of $48.0 on 01/08/2026
- Ashwani Verma from UBS set a target price of $40.0 on 11/06/2025
- Etzer Darout from Barclays set a target price of $41.0 on 11/05/2025
- Yaron Werber from TD Cowen set a target price of $51.0 on 11/05/2025
- Christopher Liu from Leerink Partners set a target price of $48.0 on 10/21/2025
- Leonid Timashev from RBC Capital set a target price of $45.0 on 10/21/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
